BMRN Stock Analysis — BioMarin Pharmaceutical
Sector: Healthcare
AI Verdict
BioMarin trades at just 11x next year's earnings despite a forecasted 169% EPS jump—this is cheap for the growth on offer if its rare disease pipeline delivers as expected.
Competitive Moat
BioMarin specializes in rare genetic disease treatments, giving it pricing power and limited competition due to high barriers in orphan drug development. Its pipeline and regulatory expertise in rare diseases make it hard for new entrants to replicate its portfolio.
Summary
BioMarin's forward P/E of 11.1x and expected 168.8% EPS growth signal a dramatic earnings inflection.
Where It Stands
BioMarin trades at 11.1x next year's earnings, far below the healthcare sector median of 22x, while analysts expect EPS to jump 168.8%.
Key Metrics
- Trailing P/E: 29.9x
- Forward P/E: 11.1x
- PEG Ratio: 0.18
- Earnings Growth: +1.7%
- Revenue Growth: +0.1%
- 52-Week High: $66.28
- 52-Week Low: $50.76
Analyst Consensus
26 Buy · 6 Hold · 0 Sell (32 analysts)
Bull Case
With a forward P/E of 11.1x and a trailing PEG ratio of 0.18, you're paying a low price for a rare growth surge.
Bear Case
If the forward P/E reverts to the sector median of 22x without delivering the 168.8% EPS growth, the stock could see a sharp de-rating.
Catalyst to Watch
Watch for clinical trial readouts or regulatory approvals—positive results could validate the huge earnings growth forecast.